bioihbjkbjnl/mcl2 huggingface dataset:
Video-game Based Therapy in Cerebral Palsy
Condition: Cerebral Palsy
MeSH terms: Paralysis; Cerebral Palsy
Study type: Interventional

Summary: 
      The video-based therapy applications; will be applied in a non-three-dimensional (with
      desktop screen) way. In this application, there are different types of exercise programs that
      will work the upper extremity movements. The video-based therapy applications will be applied
      to individuals with Cerebral Palsy (CP) who will be included in the study with the Xbox
      Kinect 3600 (Microsoft, Washington, USA) device.

      This study was planned to examine the effect of video-based therapy on upper extremity
      selective motor control and proprioception in individuals with Cerebral Palsy.
    

Detailed description: 
      Spastic CP will be participate the study between the ages of 4 and 18 years. Children's
      classified with GMFCS and MACS. The eligible participants will be allocated two groups,
      including video-game based therapy group and conventional physiotherapy control group. All
      the assessments will be performed before and after the therapy in the 8-week therapy
      groups.The control group individuals will be given a conventional physiotherapy two days per
      week for a total of 8 weeks (conventional physiotherapy session will last 45 minutes). The
      video-game based therapy group will receive a conventional physiotherapy and video-game based
      therapy, two days a week for a total of 8 weeks (15 minutes conventional physiotherapy
      session+30 minutes video-game based therapy). All sessions will be performed in the clinic
      with the specialist physiotherapist.
    

Intervention name(s): Video-game based therapy; Conventional physiotherapy
Intervention type(s): Other; Other
Intervention description(s): Video-game based therapy will be designed for the individual basis for the upper extremity.; Conventional physiotherapy within a specific program
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Cerebral palsy; Virtual reality; Video games; Upper extremity; Rehabilitation
Conventional Home Exercise Programs Versus Electronic Home Exercise Versus Artificial Intelligence "Virtual Therapy" for Anterior Knee Pain
Condition: Patellofemoral Pain Syndrome
MeSH terms: Patellofemoral Pain Syndrome
Study type: Interventional

Summary: 
      This is a clinical research trial to evaluate the efficacy of delivering exercise therapy for
      knee pain via the Internet utilizing an algorithm designed to adjust a home exercise program
      based on user input. The investigators hypothesize that exercise therapy can be delivered
      safely and effectively with increased participant satisfaction compared to the current
      standard.
    


Intervention name(s): Algorithm based Exercise Videos; PDF Exercise Sheets; Limited Exercise Videos
Intervention type(s): Other; Other; Other
Intervention description(s): The algorithm will adjust the exercises in each session based upon the participant's feedback.; A sheet of six exercises with descriptions on how to perform them properly; Video of 6 exercises that provide instruction on how to perform the exercises
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Knee pain; Anterior knee pain; Patellofemoral; Patellofemoral syndrome; Runners knee
Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring
Condition: Jaw Volume Deficit
Study type: Interventional

Summary: 
      A Multicenter, Evaluator-Blinded, No-Treatment Control Design Clinical Study to Evaluate the
      Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring
    

Detailed description: 
      This is a Multicenter, Randomized, Evaluator-Blinded, No-Treatment Control Design Clinical
      Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline
      Contouring.
    

Intervention name(s): YVOIRE Y-Solution 720
Intervention type(s): Device
Intervention description(s): Hyaluronic acid dermal filler
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Glucose:Fructose Versus Glucose Carbohydrate Ingestion and Endurance Performance
Condition: Healthy
Study type: Interventional

Summary: 
      The primary objective is to show that multiple transportable carbohydrate ingestion is more
      effective in improving endurance performance compared to single transportable carbohydrate
      ingestion.
    


Intervention name(s): Mixture of glucose and fructose; glucose
Intervention type(s): Dietary Supplement; Dietary Supplement
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science
A Singapore Pilot Study to Assess Neurovision in Treatment of Low Myopia
Condition: Myopia
MeSH terms: Myopia
Study type: Interventional
Phase: Phase 1

Summary: 
      To assess how well and safe is Neurovision technology in improving the vision of people with
      low myopia in Singapore
    

Detailed description: 
      The eye care industry has focused a majority of its resources on solving problems associated
      with the ocular or "front end" of the visual system. These investments have led to exciting
      technology advances, such as intraocular lenses (IOLs) and Laser Vision Correction (LVC) as
      well as in the development of contact lenses and improved eyewear.

      NeuroVision's innovative Neural Vision Correction (NVC) technology has been developed through
      research focused solely on optimizing performance of the neural or "back end" of the visual
      system. NeuroVision's technology is distinguished from other products in this space by the
      Company's expert understanding of how the brain processes vision, its reliance on scientific
      and clinical research

      It is the result of two decades of research by Dr. Uri Polat, founder, who has dedicated 20
      years of scientific and clinical research to understanding how the brain processes visual
      information, how neural activity is related to visual perception, and how visual processing
      interacts with other neural systems. His work has been published in leading scientific
      journals and is widely cited by the scientific community.

      NeuroVision's NVC vision correction technology is a non-invasive, patient-specific treatment
      based on visual stimulation and facilitation of neural connections responsible for vision.

      The technology has been clinically proven in the treatment of adult amblyopia ("lazy eye"),
      which until now has been considered untreatable. The Company has received FDA 510(k)
      marketing clearance indicating NVC for the treatment of adult amblyopia in patients 9 years
      or older in the US. The Company also received Medical CE-Mark to market its Amblyopia and
      Low-Myopia products in the EU. Company products are also approved for use in Israel by the
      Israeli Ministry of Health - Device License Authority.

      This study was a prospective non-controlled preliminary clinical study as a prelude to a
      randomized clinical trial, evaluating the efficacy and safety of NeuroVision NVC correction
      technology in improving visual acuity and contrast sensitivity function.
    

Intervention name(s): Neurovision
Intervention type(s): Device
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Neurovision; Myopia Therapy
Use of Theater to Invoke Empathy and Reduce Bias in Medical Students
Condition: Medical Student Bias
Study type: Interventional

Summary: 
      The effect of medical humanities on medical student bias and clinical management is unclear.
      This study characterized medical student attitudes toward obese individuals and whether
      reading a play employing empathic characters can modulate negative reactions.
    


Intervention name(s): Medical Lecture; Dramatic Reading
Intervention type(s): Behavioral; Behavioral
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Other
Valerian to Improve Sleep in Patients With Parkinson's Disease
Condition: Insomnia; Parkinson's Disease
MeSH terms: Parkinson Disease
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this trial is to test the short-term effectiveness of valerian, a medicinal
      herb, to improve sleep in patients with Parkinson's disease (PD).
    

Detailed description: 
      Patients with PD have exceptionally poor sleep. Sleep in patients with PD is characterized by
      excessive activity in surface electromyographic (EMG) recordings from many different muscle
      groups. Despite sleep disturbances, approximately 50% of patients experience a transient (1
      to 3 hour) reduction in waking motor symptoms upon arising in the morning. This effect has
      been termed Sleep Benefit. This study will evaluate the effects of valerian, a medicinal
      herb, on the sleep of patients with PD.

      This is a 17 day study where participants will be evaluated by polysomnography on days one,
      two, three, sixteen and seventeen.. Polysomnographic measurements will include customary
      variables such as total sleep time, sleep efficiency, and sleep latency, as well as EMG
      measures of periodic and isolated muscle activity during sleep. Participants will be required
      to keep a detailed sleep log of their self reported sleep characteristics across the entire
      17 study nights. Outcomes will include measures of both nocturnal sleep and waking motor
      function. Assessments of motor function will be made the morning immediately following Nights
      3 and 17 in order to test for improvement related to improved sleep. On the morning following
      Night 17, participants are provided with a one-week supply of valerian in an Open Label
      extension. Participants are provided an additional Sleep Log for this week and asked to
      return the Sleep Log when they complete the Open Label phase.
    

Intervention name(s): valerian
Intervention type(s): Drug
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Sleep
The Effects of Music Therapy as a Complementary Intervention in the Treatment of Pediatric Asthma
Condition: Asthma
MeSH terms: Asthma
Study type: Interventional

Summary: 
      The onset of asthma is particularly frightening for children. When the symptoms of asthma
      decrease, children and parents forget about the maintenance and control of breath and lung
      volume. Because adherence is so poor, asthma is known as the emergency room illness. The
      playing of a wind instrument is a unique way to provide a creative means for children and
      teens to understand both the impact of diaphramatic breathing and their ability to control it
      as well. This study builds upon the evidence, though sparse, that suggest that the blowing of
      a wind instrument with clinical music therapy intervention strengthens the muscles of
      breathing and fortifies the incentive toward attending to the daily symptoms and general
      management of asthma.
    


Intervention name(s): One time music therapy; Group music therapy
Intervention type(s): Other; Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Supportive Care
Efficacy of Pea Hull Fiber in Chronic Disease
Condition: Kidney Disease, Chronic
MeSH terms: Kidney Diseases; Renal Insufficiency, Chronic; Chronic Disease
Study type: Interventional

Summary: 
      The purpose of this study is to determine the effects of daily consumption of snacks with and
      without pea hull fiber on gastrointestinal function, gastrointestinal symptoms, food intake,
      appetite, changes in fecal and microbial composition and activity. Fifty maintenance
      hemodialysis hemodialysis and CKD patients in stage 4 or 5 will be recruited to participate
      in a randomized, blinded, 13-week cross-over study evaluating snack foods containing 15 g/d
      of pea hull fiber.
    

Detailed description: 
      Maintenance hemodialysis hemodialysis and CKD patients in stage 4 or 5 (n=50) will be
      recruited for the study. A randomized, controlled, double-blind, cross-over study will be
      carried out. Following a 1-week baseline, participants will be assigned to receive snacks
      with pea hull fiber or control followed by a 4-week wash-out period, and then crossed over to
      the second intervention. Snacks with added pea hull fiber (15 g/d) and control will be
      provided to participants in identical packaging. Participants will collect 4 days of stools
      during the baseline week, week 5, 9, and 13 and analyzed for mineral content. Microbiota
      composition will be analyzed including microbial diversity, qPCR to quantify changes and 16S
      rRNA sequencing to identify pea hull fiber effects on specific bacteria. Following baseline,
      participants will attend a second visit and anthropometric and demographic information will
      be collected and we will measure blood pressure, the body composition by bioelectrical
      impedance analysis (BIA), and handgrip strength using a dynamometer.

      Throughout the study, participants must complete a daily questionnaire to evaluate the
      transit time (eg. Bristol Stool Scale), stool frequency, and compliance. Every week,
      questionnaires to evaluate appetite (eg. SNAQ) and GI wellness (eg. GSRS - Gastrointestinal
      Symptom Response Scale) will be administered. During each study visit, participants will
      complete a questionnaire to evaluate the quality of life. In addition, the dietary data
      (24-hour diet recalls) will be collected by phone during the baseline week and during the
      last week of each period. During baseline, treatment and each washout, fasting blood will be
      collected and analyzed for a comprehensive metabolic panel with eGFR, in addition to
      microbial metabolites (e.g., indoxyl sulfate and p-cresyl sulfate), and inflammatory markers
      (e.g. CRP, TNFα, IL-6).
    

Intervention name(s): Pea hull fiber; Control
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): Snacks containing 15 g/day of ground pea hulls.; Snacks without added fiber.
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Other
Study of LY3016859 in Participants With Diabetic Nephropathy
Condition: Diabetic Nephropathy
MeSH terms: Kidney Diseases; Diabetic Nephropathies
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      The purpose of this two-part study is to investigate the safety, tolerability and efficacy of
      LY3016859 after multiple intravenous (IV) dosing's in participants with diabetic nephropathy
      (DN). Part A will be dose escalation for safety and tolerability and Part B will evaluate
      Proteinuria.
    


Intervention name(s): Placebo; LY3016859
Intervention type(s): Drug; Drug
Intervention description(s): Administered IV; Administered IV
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
Condition: Ovarian Neoplasms
MeSH terms: Ovarian Neoplasms; Carcinoma, Ovarian Epithelial
Study type: Interventional
Phase: Phase 2

Summary: 
      Regorafenib is an oral multikinase inhibitor that blocks the activity of kinases involved in
      angiogenesis (VEGFR 1,2,3 and TEK), oncogenesis (KIT, Ret Proto-Oncogene (RET), Raf-1
      Proto-Oncogene, Serine/Threonine Kinase (RAF1) and BRAF) and tumour growth (PDGFR and FGFR).
      Epithelial ovarian cancer (EOC) cell lines frequently express high levels of vascular
      endothelial growth factor (VEGF) and in vivo preclinical studies evaluating Regorafenib have
      shown promising activity in ovarian cancer. In the clinic, anti-angiogenesis therapy with
      bevacizumab (a monoclonal antibody to VEGF) has already emerged as an important cornerstone
      in the management of ovarian cancer both as part of frontline adjuvant treatment and as
      second-line therapy for platinum-sensitive recurrent disease. Whilst Regorafenib has been FDA
      approved for the treatment of patients with metastatic colorectal cancer who have failed
      prior bevacizumab, it's role in the management of ovarian cancer remains to be defined.
    

Detailed description: 
      STUDY OBJECTIVES

      The objective of this study is to evaluate the efficacy and safety of regorafenib at a dose
      of 120mg daily for 21 days out of every 28 day cycle in Asian females with multiply recurrent
      EOC.

      Primary Endpoint:

      Investigator assessed progression free survival (PFS)

      Secondary Endpoints:
    

Intervention name(s): Regorafenib
Intervention type(s): Drug
Intervention description(s): Once a day for 21 days in a 28 days cycle
Other intervention name(s): Stivarga
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: ovarian; regorafenib; platinum resistant; clear cell; endometrioid
Phase II Study Using Thalidomide for the Treatment of ALS
Condition: Amyotrophic Lateral Sclerosis; ALS
MeSH terms: Motor Neuron Disease; Amyotrophic Lateral Sclerosis; Sclerosis
Study type: Interventional
Phase: Phase 2

Summary: 
      The use of Thalidomide in patients with ALS who have disease progression.
    

Detailed description: 
      Phase II open labeled trial testing the efficacy of thalidomide for ALS in the setting of
      disease progression.
    

Intervention name(s): Thalidomide
Intervention type(s): Drug
Intervention description(s): Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
Intervention MeSH terms: Thalidomide
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: ALS
Continuation Ketamine in Major Depression
Condition: Major Depressive Disorder
MeSH terms: Depressive Disorder; Depression; Depressive Disorder, Major
Study type: Interventional
Phase: Phase 1

Summary: 
      As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of
      ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a
      relapse-prevention strategy for patients with treatment-resistant depression (TRD) who
      respond to an initial series of ketamine infusions. Ketamine is a Food and Drug
      Administration approved anesthetic (a drug used to produce loss of consciousness before and
      during surgery). Ketamine is not approved for the treatment of major depressive disorder and
      is considered experimental in this study.
    


Intervention name(s): Lithium; Ketamine
Intervention type(s): Drug; Drug
Intervention description(s): 600-900mg of Li carbonate; 0.5mg/kg of ketamine
Other intervention name(s): Lithium Carbonate; Intravenous ketamine hydrochloride
Intervention MeSH terms: Ketamine; Lithium Carbonate
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Ketamine; glutamate; N-methyl-D-aspartate; treatment resistant; major depressive disorder; lithium
Rituximab in Systemic Sclerosis
Condition: Systemic Sclerosis
MeSH terms: Scleroderma, Systemic; Scleroderma, Diffuse; Sclerosis
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      The purpose of this study is to determine whether rituximab is effective in the treatment of
      articular symptoms that occur in systemic sclerosis related polyarthritis
    

Detailed description: 
      Systemic sclerosis (SSc) is a rare disease, characterized by microvascular and immunological
      changes promoting extra-cellular matrix synthesis and widespread fibrosis. No treatment has
      yet proven any ability to alter the disease fibrosing process. Specific auto-antibodies are
      commonly found in this disease, and B lymphocytes are detected in cutaneous and pulmonary
      infiltrates. Studies derived from murine models suggest a role for B lymphocyte blocking
      strategies.

      This lead to observational trials of B-cell therapy using rituximab in SSc that provided
      encouraging results with no particular signal concerning tolerability. These trials included
      heterogeneous patients with variable disease stages and different involved organs, and were
      mostly unblinded, which preclude any definitive conclusion. However, they support the
      continuous development of this therapeutic approach.

      Taking up the early phase of the diffuse form of the disease is complicated by its rarity and
      the heterogeneous progression of its visceral complications. This raises the question of
      selecting a homogeneous group of patients to evaluate. The most convincing results for the
      use of rituximab in autoimmune conditions have been found in rheumatoid arthritis. Joint
      involvement is common in SSc with 75% of patients complaining about joint stiffness and pain,
      and 30% presenting with synovitis, tenosynovitis, or flexion contractures. No specific
      treatment has already addressed this issue, and it is generally proposed to use small doses
      of oral corticosteroids in association with methotrexate, by analogy with rheumatoid
      arthritis. We propose to evaluate the efficacy and safety of rituximab in SSc patients having
      active arthritis despite first line treatment. Improving the articular involvement would
      improve the quality of life f SSc patients and effectiveness of rituximab on skin and lung
      fibrotic involvements will be assessed as secondary outcomes to estimate the overall effects
      of this drug on SSc.
    

Intervention name(s): Rituximab; Placebo (NaCl)
Intervention type(s): Drug; Drug
Intervention description(s): Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone; Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
Intervention MeSH terms: Rituximab
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: Systemic sclerosis; Arthritis; B-cell therapy, Anti-CD20 therapy; Quality of life; Scleroderma; Lung fibrosis; Randomised controled trial
A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F®
Condition: Infertility; Anovulation
MeSH terms: Infertility; Anovulation
Study type: Interventional
Phase: Phase 3

Summary: 
      open label, active-controlled, randomized, parallel group, comparative study.
    

Detailed description: 
      This is a phase III comparative study to evaluate the effectiveness and safety of DA-3801 in
      treatment of the patients with WHO Group II anovulatory infertility failing to clomiphene
      citrate treatment. The study is conducted with following methods: open label,
      active-controlled, randomized, parallel group, comparative.
    

Intervention name(s): DA-3801 Injection; Gonal-F®
Intervention type(s): Drug; Drug
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment